A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety of GW856553 in COPD patients and to assess its affects on their COPD disease after 14 days.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Women of childbearing potential

• Established history of COPD

• Cigarette smoking history greater than 10 pack years

• FEV1 between 40 and 80% of predicted normal for height, age and sex.

Exclusion criteria:

• Morbidly obese patients (body mass index >40)

• Hospitalisation or treatment for worsening of COPD in past 6 weeks

• History of increased liver function tests

• hypersensitivity to salbutamol or ipratropium bromide

• Blood pressure > 155/95